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Aim: To assess the validity, reliability and responsiveness of two questionnaires, the QLQ-C30 
and LC-13, as measures of health-related quality of life (HRQOL) in an Australian sample of 
people with early stage non-small cell lung cancer.   
 
Background:  These two questionnaires are complementary components of the European 
Organisation for Research and Treatment of Cancer’s (EORTC’s) modular approach to measuring 
HRQOL: the QLQ-C30 is the core questionnaire, containing 30 items relevant to all cancers; the 
QLQ-LC13 contains 13 items specific to lung cancer.   
 
Methods: These two complementary questionnaires were assessed with data obtained from 183 
participants of a randomised control trial investigating the use of Positron Emission Tomography 
in the management of stage I or II non-small cell lung cancer. A cohort of 173 participants, were 
treated by surgery and then followed for two years.  Participants completed HRQOL 
questionnaires before the PET scan, before and after surgery, one month after surgery, and then 
four monthly for two years.  Construct validity was tested with confirmatory factor analysis and 
correlation analysis was used to test for convergent/divergent validity.  Discriminant validity was 
tested by assessing the sensitivity of the scales to the effects of moving from early to late stage 
disease, asymptomatic to mildly symptomatic, and to the effects of age, gender and number of 
comorbitities.  Mean differences (standardized response means (SRM)) and effect sizes were 
estimated for: patients with Stage 1/11 and  metastatic disease;  ECOG score 0 and ECOG score 
1; older and younger patients; men and women; patients with no comorbidities and those with 1 
or more comorbidities.  Reliability was assessed in terms of internal consistency and test-retest 
reliability.  Responsiveness to the effects of major thoracic surgery, adjuvant radiotherapy, and 
disease recurrence was assessed by estimating mean differences (standardized response 
meansSRM’s and effect sizes for patients who underwent surgery, radiotherapy and whose 
disease recurred, respectively.   
 
Results: The factor structure reported previously was replicated in this sample, confirming the 
questionnaires’ construct validity.  Most scales demonstrated good to excellent internal 
consistency (Cronbach’s alpha range: 0.86 – 0.94); the exceptions were the cognitive function 
(0.68) and nausea/vomiting scales (0.67).  Test-retest reliability was generally good (intraclass 
correlation (ICC) range: 0.70 – 0.81); the exceptions were the pain and nausea/vomiting scales 
(ICC 0.56 and 0.42).  Most scales were sensitive to the large effect of moving from early to later 
stage disease with (SRM range: 21.3 – 54.0; effect size range:1.14 – 1.97 (except for emotional 
functioning: 13.7; 0.60)). The scales were also sensitive to small effects, detecting small to 
moderate differences for age (large for social functioning) and comorbidities, and small 
differences for moving from asymptomatic to mildly symptomatic disease, and for age.  
Responsiveness was also confirmed with most scales responsive to the large expected effects of 
surgery and disease progression ( SRM range: 21.6 – 41.4; effect size range: 0.94 – 1.89 
(emotional functioning: 5.5; 0.19)).  
 
Conclusions: The QLQ-C30 and QLQ-LC13, when used together, provide a valid, reliable and 
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INTRODUCTION and BACKGROUND 
 
Health-related quality of life  
 
In its broadest sense, the term quality of life covers aspects of life that are beyond the scope of 
health care, such as living standards, housing, education, employment and the environment.  In 
the context of health, its meaning is restricted to aspects of welfare that relate to health and 
health care (Ware 1987; Schipper, Clinch et al. 1996).  The term health-related quality of life 
(HRQOL) is often used to differentiate the restricted from the broader sense (Wood-Dauphinee 
1999).  There is no single, concise definition of HRQOL, but it is widely accepted in the context 
of health research that HRQOL reflects the impact of disease and treatment on a person’s ability 
to function physically, socially and emotionally, and their symptom experience. 
 
Measurement of HRQOL 
 
The formal assessment of the health and well-being of individuals and populations is referred to 
as health status assessment or HRQOL assessment.  There are many instruments that measure the 
impact of disease and treatment on the HRQOL of patients.  The appropriate instrument for a 
particular application is determined by the purpose of the measurement and the kind of 
information required (Osoba, Aaronson et al. 1991; Guyatt, Jaeschke et al. 1996).  Some are 
specific to a particular disease or treatment, others are general.   
 
All measurement instruments, regardless of whether they consist of a single item, such as the 
response to a single global question, or have multiple items with multi-item scales and summary 
scores, should satisfy basic properties if they are to be considered useful.  These properties or 
attributes include validity, reliability, sensitivity and responsiveness.  They are interrelated, yet 




The validity of an instrument is “the degree to which the instrument measures what it purports to 
measure” (Lohr, Aaronson et al. 1996).  Although validity is often considered an attribute of an 
instrument, its true significance relates to the uses to which the instrument is put (Nunnally 1978; 
Fayers and Machin 2000) and the inferences that are drawn from resultant scores (Streiner and 
Norman 1996).  An instrument should be validated for every intended purpose.   
 
Validity can be subdivided into three main aspects, namely content, criterion and construct 
validity.  However, the methodology and terminology of validity are complex and there is often 
overlap in the meanings of terms and the evidence provided by various methods.   
 
Content validity is the extent to which the items of the instrument cover the range of issues that 
are relevant to its intended use (Fayers and Machin 2000).  The more representative the sample 
of items, the more likely the instrument will yield inferences that hold true in a wide range of 
circumstances (Streiner and Norman 1996).  The wording of items and response scales should be 
unambiguous, and redundancy should be minimised.  Face validity is a closely related concept.  
The distinction is that content validity is determined during the development of an instrument 
while face validity is a used as criterion when choosing among existing instruments for a specific 




Construct validity is the extent to which the relationships observed among variables conform 
with hypothesised relationships (Streiner and Norman 1996; Fayers and Machin 2000).  There 
are two main types of evidence.  The first tests hypothesised relationships among latent 
variables.  Evidence is generally sought by correlation of observed variables: correlations 
between items in the same scale, correlations between an item and items in other scales, 
correlations between a scale score and its constituent items, and correlations among scales of one 
or more instruments.  Convergent validity is supported by correlation among measures of latent 
variables that are hypothesised to be similar.  Discriminant validity is supported by lack of 
correlation among measures of latent variables that are hypothesised to be dissimilar.  Common 
methods of analysis include factor analysis, path analysis, multitrait-scaling analysis and 
multitrait-multimethod analysis. 
 
The second form of evidence supports hypothesised relationships between latent variables and 
external criteria.  For example, patients with early stage cancer may be expected to have better 
QOL than patients with advance cancer.  This type of evidence is said to support clinical validity 
or “known-groups” validity because groups of patients are often defined by clinical criteria.  This 
also provides evidence of the sensitivity of a scale to clinically important differences.  This has 
also been called discriminative validity (Stockler, Osoba et al. 1999). 
 
Criterion validity is the extent to which a measure corresponds to an external criterion (Nunnally 
1978; Streiner and Norman 1996; Fayers and Machin 2000).  Criterion validity can be divided 
into two aspects.  Concurrent validity means agreement with a true value, or “gold standard”, 
which does not exist for QOL.  If a short version of an established questionnaire is being 
developed, the long version may be considered the standard.  Predictive validity concerns the 
ability of an instrument to predict future health status or future events (such as hospitalisation or 




The reliability of an instrument is its ability to yield reproducible and consistent results (Fayers 
and Machin 2000). Formal definitions of reliability involve notions of random variation or 
measurement error.  In QOL assessment, random variations may include real but transient 
variations in health or circumstance or in the perception of health or circumstance.  Measurement 
error may be due to scale coarseness in approximating the continuous latent variable and 
inconsistent use of the scale by the respondent.   
 
The consistency of the items in a multi-item scale as measures of the latent variable is called 
internal consistency.  There are many measures of internal consistency, Cronbach’s alpha 
coefficient being the most commonly used (Hattie 1985).  Internal consistency is in many senses 
a form of validity (Fayers and Machin 2000) and is commonly estimated and reported along with 
construct validity. 
 
Another type of reliability is the reproducability or stability of scores on a scale when the 
circumstances of assessment differ but the patient’s QOL does not.  Circumstances may include 




Reproducability across repeated measurements is commonly called test-retest reliability.  One of 
the difficulties with estimating test-retest reliability for QOL measures is identifying the 
appropriate patient population and period.  The period must be long enough so respondents do 
not remember their responses to questions, and short enough so that their QOL has not changed.  
Reproducability is often assessed with kappa for discrete data, or the intra-class correlation 




The responsiveness of an instrument is its ability to detect change (Lohr, Aaronson et al. 1996).  
Responsiveness is tested and calibrated in situations where clinically meaningful change is likely 
to occur, such as a treatment of known effectiveness administered to patients who are likely to 
respond (Liang, Larson et al. 1985; Deyo, Diehr et al. 1991) or disease progression as part of the 
natural history of a disease.  The most commonly used responsiveness measures are the mean 
change (standardised response mean) proposed by Liang et al (1990) and effect size, proposed by 
Kazis et al (1989).    
 
Measuring HRQOL in cancer care 
 
Traditionally, the evaluation of cancer treatments focused on biomedical outcomes such as tumor 
response, time to progression, disease free and overall survival rate and treatment related 
toxicities.  However, it has now become increasingly accepted that the measurement of HRQOL 
needs to be included if we are to obtain a comprehensive evaluation (Osoba 1995).    
 
The measurement of HRQOL in the area of cancer care is particularly important because the 
physical and psychological effects of the disease, and the benefits and toxicities of cancer 
treatments (Schipper and Clinch 1988; Fallowfield 1990; Cella and Tulsky 1993b; Cleton 1995; 
Greco 1995; Hanks and Hoskin 1995; Maguire 1995; Steel 1995) have a direct effect on patients’ 
wellbeing and their ability to perform their usual roles and abilities.  There are several 
instruments that measure HRQOL in this area.  One of the most recommended instruments is the 
European Organization for Research and treatment of Cancer Quality of Life Questionnaire Core 
module (EORTC QLQ-C30) (Aaronson, Ahmedzai et al. 1993).   
 
The QLQ-C30 was developed by the EORTC Study Group for Quality of Life (Aaronson, 
Bullinger et al. 1988; Aaronson, Ahmedzai et al. 1991a; Aaronson, Ahmedzai et al. 1993).  It is 
the core component of the EORTC’s modular approach to QOL assessment and represents QOL 
domains relevant across a wide range of cancer sites and treatment types.  The QLQ-C30 is 
complemented by modules specific to particular cancers such as lung cancer and breast cancer.  
The core module facilitates comparison across the diversity of trials administered by the 
EORTC, and the disease-specific modules provide sensitivity for particular trials (Aaronson, 
Cull et al. 1996).   
 
From it’s beginnings as the first generation QLQ-C36 (Aaronson, Ahmedzai et al. 1991a) to the 
current version QLQ-C30 v3 (Aaronson, Ahmedzai et al. 1993), it has undergone a continual 
process of development and validation.  It has been found to have good to excellent validity, 
reliability, sensitivity and interpretability, and has been used in a wide range of cancer trials as 
well as other various non-trial studies world wide.  A bibliography of validation studies can be 
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found in the EORTC QLQ-C30 scoring manual (Fayers, Aaronson et al. 2001) and a summary of 
findings from numerous studies can be found in Spilker et al (Spilker 1996). 
 
The lung cancer module, the QLC-LC13, is meant for use with a wide variety of lung cancer 
patients in varying disease stage and treatment modality (Bergman, Aaronson et al. 1994).  This 
was the first module developed to address specific symptoms associated with a particular cancer 
and its treatment.  It was constructed in parallel with, and validated in field tests together with 
the QLQ-C30 (Bergman, Aaronson et al. 1994), and has subsequently been validated in other 
studies (Chie, Yang et al. 2004; Nowak, Stockler et al. 2004).      
 
Ongoing validation of the EORTC QLQ-C30 and the EORTC QLQ-LC13 
 
The validity of a HRQOL instrument is not something that is established by a single or even a 
few studies.  Whether or not the instrument produces sensible and useful results in various 
circumstances should be judged in an ongoing process of validation (Streiner and Norman 1996; 
Fayers and Machin 2000).  Although the EORTC QLQ-C30 and the EORTC QLQ-LC13 have 
undergone a continual process of validation across a range of health care contexts and disease 
groups, and in different nationalities and cultures, our confidence in, and understanding of, the 
instruments will develop as the body of evidence accrues.   
 
In most instances, HRQOL instruments are validated in studies or trials designed specifically for 
validation purposes.  However, researchers can also use data from existing studies, designed for 
other purposes, to validate an instrument.  An Australian randomized clinical trial (RCT) 
designed to investigate the role of Positron Emission Tomography (PET) in the management of 
early stage non-small cell lung cancer (NSCLC)  provided a good opportunity to validate the 
QLQ-C30 and the QLQ-LC13 in this population.   
 
RCT to investigate PET in the management of early stage Non-Small Cell Lung cancer 
(NSCLC) 
 
NSCLC represents approximately 80% of all lung cancer.  Approximately 25% of patients 
present with what appears to be resectable disease, but relapse is common with up to 40% of 
patients with Stage 1 and 60% of patients with Stage 2 disease at surgery experiencing disease 
recurrence following surgical resection.  These patients went through the trauma of major 
thoracic surgery without the cure that was hoped for; in that sense, their thoracotomies were 
futile. 
 
Positron emission tomography (PET) is a relatively new imaging technology with the potential to 
improve pre-operative staging.  Many malignant tumours show increased glucose utilisation 
when compared to normal tissues (Nolop, Rhodes et al. 1987).  Whole body PET with 
18F-
fluorodeoxyglucose (FDG) can identify regions of increased glucose metabolism in non-enlarged 
structures, allowing detection of tumour metastases earlier than with anatomic imaging methods.  
Data suggest PET may improve the accuracy of pre-operative staging of NSCLC, but, in general, 
these are from small, retrospective, uncontrolled series (Wahl, Quint et al. 1994; Weder, Schmid 
et al. 1998; Saunders, Dussek et al. 1999).  A recent prospective uncontrolled study reported 
sensitivity and specificity of PET for detection of mediastinal and distant metastatic disease of 95 
per cent and 83 per cent, respectively (Pieterman, van Putten et al. 2000).  PET is costly, and 
resource implications of its widespread use in staging NSCLC are significant.  There is 
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increasing pressure for PET to be included in the standard diagnostic work-up prior to decisions 
about surgical management of NSCLC (Robert and Milne 1999; Berlangieri and Scott 2000). 
 
In the first randomised controlled trial of patients with a clinical diagnosis of Stage I-II of 
NSCLC, 184 patients were recruited and randomised.  Following exclusion of one ineligible 
patient, 92 patients were assigned to no-PET and 91 to PET.  Of these, 173 were treated by 
surgery.  Compared with conventional staging PET upstaged 22 patients, confirmed staging in 61 
and staged two patients as benign.  Stage IV disease was rarely detected (2 patients).  PET led to 
further investigation or a change in clinical management in 13% of cases, and provided 
information that could potentially have affected management in a further 13% of cases.  There 
was no significant difference between the trial arms in the number of thoracotomies avoided 
(p=0.2).  It was concluded that for patients who are carefully and appropriately staged as having 
stage I-II disease, PET provides potential for more appropriate stage-specific therapy, but may 
not lead to a significant reduction in the number of thoracotomies avoided.  A full report of the 
RCT is available in a paper by Rosalie Viney et al (Viney, Boyer et al. 2004). 
 
Further research conducted using the RCT sample 
 
HRQOL data was collected at recruitment from all 183 patients eligible to participate in the 
RCT.  A cohort of 173 participants who were treated by surgery was then followed for two years.  
During this period, clinical outcomes, resource utilization and HRQOL were measured.  The 
HRQOL data was evaluated from two angles.   
 
The first aim was to describe the HRQOL in this patient group; these analyses are published 
elsewhere (Kenny, King et al. 2008).  
 
The second aim was to describe the measurement properties of the HRQOL instruments.  
Specifically, to assess the validity, reliability and responsiveness of the QLQ-C30 and QLQ-
LC13, as measures of HRQOL in an Australian sample of people with early stage NSCLC.  




Recruitment and data collection 
 
Participants in this study were 183 patients recruited from the practices of six thoracic surgeons 
in Sydney, Australia between April 1999 and December 2000.  The patients were participating in 
a randomised controlled trial to investigate the impact of Positron Emission Tomography (PET) 
on the clinical management and surgical outcomes for patients with a clinical diagnosis of Stage 
I or II NSCLC.  The trial found no significant difference in management between the 
intervention and control groups (Viney, Boyer et al. 2004).  Of the 183 participants, 173 were 
treated by surgery and then followed for two years.  The study was approved by the relevant 
institutional ethics committees. 
 
The EORTC QLQ-C30 version 3 (Aaronson, Ahmedzai et al. 1993), and the EORTC QLQ-
LC13 (Bergman, Aaronson et al. 1994) were used to measure HRQOL.  Questionnaires were 
self-completed at recruitment to the study, at hospital admission and discharge, one month and 
four months after surgery and then every four months until two years after surgery.  Additional 
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assessments were completed at the beginning and end of adjuvant therapy and participants 
diagnosed with recurrent disease were asked to complete monthly assessments for as long as 
possible, in order to capture changes within the four-month period.  Preoperative and discharge 
assessments were completed at the clinic or hospital and the remaining assessments were 
completed by postal survey.  Socio-demographic characteristics were collected at the recruitment 
interview and clinical information was collected from individual hospital medical records, from 




The EORTC QLQ-C30 and the EORTC QLQ-LC13 were chosen because they were developed 
in a sound, rigorous way, and had been shown to be valid and reliable.  The QLQ-C30 core 
questionnaire is a generic cancer instrument that contains 30 items relevant to all cancers.  The 
QLQ-LC13 is a lung cancer module that contains 13 items specific to lung cancer.   
 
The QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical – five items, 
Role – two items, Emotional – four items, Social – two items, Cognitive functioning – two 
items): three symptom scales (Fatigue – three items, Pain -two items, and Nausea and Vomiting 
– two items); and a Global Health Status/QOL scale- two items.  It also includes six single items 
that assess symptoms commonly reported by cancer patients (Dyspnoea, Insomnia, Appetite loss, 
Constipation, Diarrhea and Financial difficulties).  The first 28 items have a four-point Likert 
response scale, namely ‘not at all’, ‘a little’, ‘quite a bit’ and ‘very much’.  The last two items, 
rating overall health and overall quality of life during the past week, have a response scale 
ranging from 1 (very poor) to 7 (excellent). (Fayers, Aaronson et al. 1999)  The questionnaire 
takes approximately 11-12 minutes to complete.   High scores on the functioning scales indicates 
good functioning, high scores on the symptom scales indicates worse symptoms. 
 
The QLQ-LC13 comprises: one multi item scale, Dyspnoea, which has three items, and nine 
single items (Coughing, Haemoptysis, Sore mouth, Dysphagia, Peripheral neuropathy, Alopecia, 
Pain in chest, Pain in arm/shoulder and Pain in other parts).  The first 12 items have a four-point 
Likert response scale, namely ‘not at all’, ‘a little’, ‘quite a bit’ and ‘very much’.  Item 12 also 
includes an open ended question following the initial response.  Item 13 is also composed of two 
parts.  It begins with a ‘yes’,  ‘no’  response format,  followed by a four-point response scale of  
‘not at all’, ‘a little’, ‘quite a bit’ and ‘very much’ for those who answered ‘yes’. (Fayers, 
Aaronson et al. 1999).  As for the QLQ-C30, high scores on functioning scales indicate good 
functioning, high scores on the symptom scales indicate worse symptoms.  
 
Analysis   
 
The sample baseline socio-demographic and clinical characteristics were described and the 
proportions receiving subsequent therapies, diagnosed with lung cancer recurrence and dying 
during follow-up were reported.  A range of analyses was carried out to confirm the validity, 
reliability and responsiveness of the EORTC QLQ-C30 and the EORTC QLQ-LC13 
questionnaires. The main focus of these analyses is on the multi-item scales, although the single 
items scores are used for some analyses. 
 
The QLQ-C30 and QLQ- LC13 items were summarised into scales as per the scoring manual 
(Fayers, Aaronson et al. 2001).  All multi-item scales are the mean score of the relevant items 
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transformed to a score between 0 and 100.  A higher score represents better quality of life for the 
global health status and functional scales and worse quality of life (more symptoms) for the 
symptom scales.   
 
The pattern and extent of missing assessments were reported for nine time-points (preoperative, 
hospital discharge, 1, 4, 8, 12, 16, 20 and 24 months after surgery).  For those who had surgery, 




There are several types of validity. A range of analyses was conducted to test the construct, 





Construct validity is reflected in the relationships of the items and the domain scales. These 
relationships have been specified for both of these instruments by the EORTC, and are 
summarized as measurement models.  Confirmatory factor analysis (CFA), which is a correlation 
analysis conducted on item-level data, was conducted to test the EORTC measurement models 
for our sample.  The domain scores at the last time-point for each person were used for this 
analysis. 
 
Various fit indices were produced including the Goodness of Fit Index (GFI)(Joreskog 1993; 
Tanaka 1993), the Adjusted Goodness of Fit Index (AGFI), which takes into account the degrees 
of freedom available for testing the model, and the Comparative Fit Index (CFI) (Bentler 1990). 
In all of these, a value of 1 indicates perfect fit and values over 0.95 for GFI  and 0.90 for AGFI 
and CFI are generally thought to indicate adequate fit (Arbuckle and Wothke 1999; Hu and 
Bentler 1999). The Chi-square distribution and Root Mean Square Error of Approximation 
(RMSEA)(Browne and Cudeck 1993), were also calculated. These indices measure how badly 
the proposed model fits the data.  For the RMSEA, a value of 0.00 indicates a perfect fit, values 
of 0.08 or less indicate a reasonable fit and 0.05 or less a well fitting model (Browne and Cudeck 
1993).  The internal consistency of each domain scale was measured using the Cronbach’s alpha 
statistic.  Values above 0.7 are generally regarded as acceptable, over 0.8 good, and over 0.9 
excellent (Fayers and Machin 2000).   
 
Convergent and Divergent validity 
 
Convergent and divergent validity is tested by a priori expectations about the relationships 
among domain scales. In this sample it was expected that there would be a moderate correlation 
among the physical-based functioning scales and the symptom scales, and among the 
psychosocial scales.  The correlation among the physical and psychosocial scales was expected 
to be lower. Correlation analysis was conducted on domain-level and single item data (from the 
last timepoint for each person), specifically the correlation matrix of all multi-item scales and 
single items of the QLQ-C30 and the QLQ- LC13.  Correlations from 0.10 to 0.29 are generally 






Discriminant validity is tested by a priori expectations about groups known to differ in clinically 
relevant ways. The following a priori expectations were specified for this sample:  
 
1) patients with newly diagnosed Stage I or  II disease would have much better HRQOL 
across all domains than patients with metastatic disease;  
 
2) patients who were asymptomatic at recruitment (as recorded by a clinician-rated ECOG 
performance status of zero) would have slightly better HRQOL across all domains than 
patients who were symptomatic at recruitment but whose symptoms had little or no impact 
on their daily function (as recorded by a clinician-rated ECOG performance status of one);   
 
3) at recruitment, the HRQOL of older patients would be lower than for younger patients for 
all physical but not psychosocial domains; 
  
4) at recruitment, men would have a slighter better HRQOL (about 5 points) than women; 
 
5) HRQOL at recruitment would be inversely related to the number of comorbidities. 
 
The first expectation constitutes a clinically “large” effect while the other expectations constitute 
a clinically “small” effect.  Mean differences (in HRQOL scale units) and effect sizes (mean 
difference divided by the between-person standard deviation) were estimated to test these 
expectations.  
 
The sensitivity of the scales to the large effects of moving from early to late stage disease was 
tested with the HRQOL data at recruitment for the 113 patients whose disease did not progress 
contrasted with the HRQOL data from the last observation for the 45 patients whose disease did 
progress.  The sensitivity of the scales to the small effect of moving from asymptomatic to 
mildly symptomatic was tested with the HRQOL data at recruitment of patients with ECOG 0 
status contrasted with patients with ECOG 1 status.   
 
HRQOL data at recruitment was also used to test the sensitivity of the scales to gender, age and 
comorbidities.  For all expectations, significance testing was also conducted to determine if the 
differences were significantly different.  All analyses were conducted on domain level data.   
Confidence intervals were determined for all estimates.  King has suggested the following 
guidelines for determining the significance of the mean differences when the QLQ-C30 and  
QLQ-LC13 are used:  For all but three scales (role, emotional and cognitive functioning), a 
difference of up to 2 points is unlikely to have clinical relevance ("trivial"), a difference of about 
5 points is relatively small but may be clinically important ("small"), a difference of about 10 
points is likely to have clinical significance ("moderate"), and a difference of 15 or more is 
relatively large and has clear clinical relevance ("large") (King 1996).  For the role functioning 
scale, the values are 5, 10, 15 and 25.  There is insufficient evidence to judge the relative effect 
size for the emotional and cognitive functioning scales.  The empirical effect sizes are generally 






Test-retest reliability, which assesses measurement stability over time, is relevant to many health 
research applications because we often need to detect clinically important change over time and 
we need to be sure that the degree of change detected is greater than that expected by chance.  
Despite its importance, there is relatively little empirical evidence about the test-retest reliability 
of HRQOL instruments generally, and these two instruments in particular. Assessing test-retest 
reliability requires a sub-sample of patients and time points where HRQOL is expected to remain 
stable.  Therefore HRQOL data at recruitment to the RCT and at admission to hospital, which 
was generally about a week later, was used.  Data from participants who had a positive PET scan 
or any other clinically relevant episode between recruitment and admission, were excluded from 
the analysis, as any such events may have altered some aspects of their HRQOL.   
 
The summary measure for test-retest reliability is the intra-class correlation coefficient, which is 
derived from a repeated measures ANOVA.   The mean change in the test-re-test data was also 
examined, as this suggests the degree of change that may be expected by chance for each scale.     
Internal consistency, which assesses the degree of correlation of the items with a multi-item 
scale, was measured with cronbach’s alpha.  All analyses were conducted on domain level data.  
Confidence intervals were determined for all estimates.  ICC’s of 0.70 were considered 




Responsiveness is the ability of an instrument to detect clinically important change. It is a key 
measurement property for any instrument that is used to evaluate the effect of health 
interventions on HRQOL in longitudinal studies. A scale that fails to detect a clinically important 
change when it occurs is worse than useless.  Despite its importance, there is relatively little 
empirical evidence about the responsiveness of HRQOL instruments generally, and these two 
instruments in particular.  Instrument responsiveness can be assessed and characterized by 
identifying groups of patients whose clinical status is known to have changed during a given 
time period and considering the change in their HRQOL scores over that period.  This sample 
provided the opportunity to assess responsiveness to the well-known clinical effects of surgery, 
disease recurrence and adjuvant radiotherapy.  The relevant analyses are similar to those for 
discriminant validity, but in this case the parameter of interest is the mean change over time and 
the effect size is calculated as the mean change divided by the between-person standard deviation 
(at the first of the two observations).  This version of effect size is sometimes called the 
standardized response mean. 
 
HRQOL data at the following time points were used to estimate the mean change and effect 
sizes: surgery - admission and discharge; disease recurrence - recruitment and first and last 
observation following recurrence; adjuvant radiotherapy – recruitment and first and last 
radiotherapy treatment.  All analyses were conducted on domain level data.  Confidence intervals 








The sample comprised 183 patients participating in the randomised controlled trial investigating 
the impact of PET on the clinical management and surgical outcomes for patients with Stage I or 
II NSCLC.  Of these, 173 underwent surgery and had a post-operative diagnosis of lung cancer. 
Five patients died before discharge, reflecting the small but ultimate risk that surgery poses for 
some patients.  A further 62 patients (37%) experienced disease recurrence within two years and 
only 20 were still alive two years after surgery.  Of the remaining 106 patients, 15 died of other 
causes, eight were lost to follow-up and 83 were disease free at two years.   
 



























Not cancer 5 
No surgery 5 
Died in hospital 
5 
Recurrent cancer  
62 
No diagnosis of 
recurrence




Lost to follow-up 
4 




Lost to follow-up 
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Sociodemographic and clinical characteristics 
 
The sociodemographic, clinical and treatment characteristics of the sample are presented in 
Table 1.  The sociodemographic profile was as expected given the type of cancer.  The sample 
comprised mainly older men who had smoked most of their lives.  Education levels were low, 
few had private health insurance, some had Department of Veterans Affairs cards, most were 
married and born in Australia.   
 
The clinical profile was also typical. Although all had initially been diagnosed as Stage I or II 
preoperatively on the basis of clinical signs, almost a quarter were found to have more extensive 
disease at definitive diagnosis post-surgery.  Over a third (36%) experienced disease progression 
during the two year follow-up period, and about the same number (34%) died.  A quarter 
received adjuvant radiotherapy, a fifth received palliative radiotherapy, and almost a tenth 
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The number providing data at each time-point declined throughout the follow-up period, due 
largely to death rather than missing data (Table 2).  Ten participants (6%) did not contribute data 
to the HRQOL analysis (3 had no data and 7 had no postoperative data).   Forty-three percent 
completed all HRQOL assessments and a further 13% completed all assessments until death.  
Not surprisingly, the attrition rate over the two years of the study was greater for the recurrence 
group.  Of 62 participants diagnosed with recurrence, 94% completed HRQOL preoperatively, 
50% at one year and 27% at two years.  Of 106 participants without recurrence, 97% completed 
HRQOL preoperatively, 76% at one year and 74% at two years.  The rate of missing data ranged 
from 6% to 21% for those with recurrence and 3% to 16% for those without disease recurrence 
(see Table 2). 
 
Distribution of HRQOL scores 
 
Inspection of skewness and kurtosis values, histograms, and box and normality plots, revealed 
several variables were not normally distributed.  Significance testing with data that was not 
normally distributed was conducted using non parametric methods, namely Kruskal Wallis 
ANOVA and Mann Whitney U tests. 13 
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Confirmatory factor analysis (CFA) was conducted on the physical functioning and emotional 
functioning scales of the EORTC QLQ-C30.  CFA was not conducted on the two and three item 
scales of the EORTC QLQ-C30 and EORTC QLQLC-13 because three has been suggested as 
the minimum number of items with which to conduct a CFA (Hatcher 1994).  
 
The CFA conducted on the physical functioning and emotional functioning scales of the QLQ-
C30 suggest that the measurement models specified by the EORTC for these scales were 
generally replicated in this sample.  Indices of goodness of fit varied but were mostly adequate 
or better. Internal consistency was shown to be robust.   
 
The results of the CFA for the QLQ-C30 physical functioning scale are presented in Figure 2.  
All five items loaded with critical ratios greater than two so are appropriate in the model.  The 
standardized regression weights were above the 0.32 minimum (Tabachnick and Fidell 2001).  
The factor loadings for four of the five items were above 0.50, with three of these being above 
0.75.  Item five however only loaded at 0.39 (i.e. only 15% of the variance for this item was 
explained by the factor).  Fit indices ranged from poor ( RMSEA = 0.113), to borderline (AGFI 
= 0.88), to good (GFI = 0.96, CFI = 0.92).  The internal consistency statistic (Cronbach's alpha) 
for the multi-item scale was good (α = 0.87).  Cronbach’s alpha would increase (α = 0.88) if item 
5 was deleted.  
 
 
Figure 2.  Measurement model for the EORTC QLQ-C30 physical functioning scale showing 
parameter estimates and factor loadings for each item in the scale. 
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The results of the CFA for the EORTC QLQ-C30 emotional functioning scale are presented in 
Figure 3.  All measures suggested an excellent fit.  Factor loadings for the four component items 
ranged from 0.81 to 0.85 showing that 65% or more of the variance for each of the items was 
explained by the factor.  Fit indices were excellent (GFI = 0.99, AGFI = 0.96, CFI = 1.00, 
RMSEA = 0.00).  Cronbach’s alpha for the multi-item scale was good (α = 0.90).   
 
 
Figure 3.  Measurement model for the EORTC QLQ-C30 emotional functioning scale showing 
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Cronbach’s alpha for the two and three item scales ranged from acceptable (Cognitive 
functioning: α = 0.68; Nausea/vomiting: α = 0.67), to good (Social: α = 0.86; Pain: α = 0.87),  to 
excellent (Role: α = 0.94;  GHS: α = 0.94;  Fatigue: α = 0.91).   
 
The factor loadings for the three component items of the EORTC QLC-LC13 ranged from 0.58 
to 0.93.  Cronbach’s alpha was good (0.89). 
 
The measurement models were then included in the structural models for the EORTC QLQ-C30 




The initial EORTC QLQ-C30 structural model for one domain for quality of life (Figure 4) did 
not fit well.  This model included the multi-item scales and the single items.  It consisted of 5 
functional scores, 1 global health score and 9 symptom scores.  Initial analysis indicated that, for 
most of the items, factor loadings ranged from 0.71 to 0.94.  Exceptions were constipation and 
diarrhea with factor loadings of 0.52 and 0.24 respectively.  However, there were significant 
correlations between the error terms on: role functioning and social functioning (0.44); 
emotional functioning, appetite loss and nausea and vomiting (0.30 and 0.38); dyspnoea and 
financial difficulties (0.16); and pain and constipation (0.11).  This usually indicates these 
relationships may represent another construct and should only be covaried if there is 





Figure 4.  The initial EORTC QLQ-C30 structural model for one domain for QOL showing 
parameter estimates and factor loadings for each multi-item scale and single item, and significant 






The model was then fitted to the multi item scores only (Figure 5).  Results were mixed.  Factor 
loadings ranged from 0.67 to 0.91.  There were significant correlations between the error terms 
on role functioning and social functioning (0.36), and on emotional functioning and cognitive 
functioning (0.16).  Fit indices were varied.  Chi square was statistically significant ( χ
2 = 38.6, 
df = 25, p = 0.04) indicating the model did not fit well.  Other indices were borderline (GFI = 
0.94,  AGFI = 0.89),  to good (CFI = 0.91, RMSEA = 0.056).       
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Figure 5.  The EORTC QLQ-C30 structural model fitted to multi-item scores only, showing 
parameter estimates and factor loadings for each multi-item scale, and significant correlations 




























The initial EORTC QLQLC-13 structural (Figure 6) for one domain for quality of life did not fit 
well.  The model consisted of 10 symptom scores.  Several items (sore mouth, haemoptysis, 
peripheral neuropathy and alopecia) loaded with critical ratios less than 2.  Chi square was 
statistically significant ( χ
2  = 55.64, df = 35, p = 0.02) indicating the model did not fit well.  
Other indices were poor (CFI = 0.75), to borderline (GFI = 0.91, AGFI = 0.86), to good 
(RMSEA = 0.058).    
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Figure 6.  The initial EORTC QLQ-LC13 structural model for one domain for QOL. 
 
            
 
 
To improve the model, items 4 (sore mouth) and 7 (alopecia) were removed (Figure 7).   Factor 
loadings then ranged from 0.53 to 0.73 except for coughing (0.26) and haemoptysis (0.28).   Fit 
indices were varied. Chi square indicated an adequate fit (χ
2 = 26.3, df = 20, p = 0.157).  Other 
indices ranged from borderline (GFI = 0.95) to adequate (AGFI = 0.90, CFI = 0.90), to good 
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Figure 7. The improved EORTC QLQ-LC13 structural model for one domain for QOL showing 
parameter estimates and factor loadings for the multi-item scale dyspnoea and single items 
(minus sore mouth and alopecia).    
 
         
 
 
Convergent and Divergent validity     
 
To test the convergent and divergent validity of the EORTC QLQ-C30 and the EORTC QLQ-
LC13, correlation analysis was conducted on all multi-item scales and single items using the last 
time-point for each person.  It was expected that there would be a moderate correlation among 
the physical-based functioning scales and the symptom scales, and among the psychosocial 
scales.  The correlation among the physical and psychosocial scales was expected to be lower.  
 
Results of the correlation analysis are reported in Tables 3-5.  Correlations among the scales and 
single items of the QLQ-C30 (Table 3) were generally consistent with expectations (except 
between the physical and psychological scales), although they tended to be strong rather than 
moderate.  More than 50% of the correlations among the physical-based functioning scales and 
the symptom scales were strong ranging from 0.50 to 0.81, and about 25% were moderate, 
ranging from 0.31 to 0.47.  Among the psychological scales all correlations were strong (0.54 to 
0.66), as were all correlations between the physical and psychological scales (0.52 to 0.80).  
Generally, correlations between the symptom single items and the multi-item function scales 
were the lowest with the majority being less than 0.50.  
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Table 3.  Correlations among the EORTC QLQ-C30 scales and single items 
 
  XPF XRF XEF XCF XSF XQL XPA XNV XFA XDY XSL XAP XCO XDI XFI 
XPF 1.00           
XRF  0.81  1.00          
XEF  0.52 0.53 1.00           
XCF  0.58 0.63 0.55 1.00         
XSF  0.71 0.80 0.61 0.59 1.00       
XQL  0.76 0.71 0.56 0.54 0.66 1.00      
XPA  -0.71 -0.73 -0.53 -0.53 -0.64 -0.68 1.00      
XNV  -0.54 -0.55 -0.38 -0.37 -0.59 -0.52 0.50 1.00      
XFA  -0.80 -0.78 -0.65 -0.62 -0.72 -0.72 0.70 0.57 1.00      
XDY  -0.71 -0.62 -0.41 -0.45 -0.61 -0.55 0.46 0.40 0.60 1.00      
XSL  -0.51 -0.52 -0.52 -0.44 -0.50 -0.56 0.61 0.39 0.55 0.36 1.00      
XAP  -0.55 -0.54 -0.44 -0.41 -0.60 -0.49 0.46 0.56 0.59 0.42 0.47 1.00      
XCO  -0.50 -0.53 -0.49 -0.41 -0.55 -0.44 0.59 0.33 0.53 0.31 0.50 0.47 1.00     
XDI  -0.11 -0.08 -0.10 -0.10 -0.20 -0.12 0.01 0.20 0.13 0.12 0.13 0.19 0.03 1.00  
XFI  -0.34 -0.36 -0.47 -0.29 -0.44 -0.39 0.31 0.34 0.37 0.33 0.34 0.35 0.25 0.15 1.00 
 
Approximate 95% confidence intervals are as follows: 0.90 (0.85, 0.93);  0.80 (0.72, 0.86);  0.70 




Correlations among the EORTC-LC13 symptom scales and single items (Table 4) were fairly 
consistent with expectations, although there were slightly more small correlations than moderate 
correlations.  This is consistent with the correlations between scales and single items of the 
QLQ-C30.  About 42% were small (0.12 to 0.29), and 40% moderate (0.31 to 0.47).   
 
 
Table 4.  Correlations among the EORTC-LC13 scales and single items 
 
  XLDY XLCO XLHA XLSM XLDS XLPN XLPO XLAS XLCH XLAL 
XLDY  1.00      
XLCO  0.41  1.00     
XLHA  0.29  0.25  1.00    
XLSM  0.46  0.18  0.31  1.00   
XLDS 0.47  0.40  0.15  0.55  1.00   
XLPN  0.35 0.07 0.00 0.31 0.21 1.00 
XLPO  0.35 0.23 0.18 0.28 0.32 0.21 1.00
XLAS  0.35 0.01 0.14 0.28 0.12 0.42 0.37 1.00
XLCH  0.54 0.25  0.2 0.36 0.41 0.36 0.39 0.47 1.00
XLAL  -0.25 0.13 0.02 0.31 0.17 0.29 0.12 0.12 0.24 1.00
 
Approximate 95% confidence intervals are as follows: 0.90 (0.85, 0.93);  0.80 (0.72, 0.86);  0.70 






Correlations among the scales and single items of the EORTC QLQ-C30 and QLQ-LC13 (Table 
5) were generally consistent with expectations (except between the physical and psychological 
scales).  Almost 50% of the correlations among the physical-based functioning scales and items, 
and the symptom scales and items were moderate ranging from 0.30 to 0.49.  Correlations 
among the scales only were higher with about 50% being strong (0.53 to 0.82).  Between the 
physical and psychological scales and items more than 60% of the correlations were moderate ( 
0.30 to 0.49).  Again correlations among the scales alone were higher (0.50 to 0.67).   
 
 
Table 5.  Correlations between the scales and single items in the EORTC QLQ-C30 and the 
EORTC-LC13 
 
  XPF XRF XEF XCF XSF XQL XPA XNV XFA XDY XSL XAP XCO XDI  XFI 
XLDY  -0.77 -0.63 -0.50 -0.47 -0.67 -0.62  0.53 0.46 0.67 0.82 0.40 0.47 0.43 0.09 0.35 
XLCO  -0.35 -0.32 -0.22 -0.13 -0.35 -0.35  0.24 0.30 0.33 0.37 0.19 0.35 0.23 0.04 0.21 
XLHA  -0.31 -0.27 -0.22 -0.24 -0.28 -0.25  0.21 0.30 0.27 0.25 0.2 0.31 0.25 0.07 0.06 
XLSM  -0.41 -0.39 -0.49 -0.39 -0.40 -0.36  0.35 0.38 0.40 0.37 0.29 0.33 0.25 0.06 0.26 
XLDS  -0.45 -0.45 -0.41 -0.41 -0.47 -0.44  0.40 0.56 0.45 0.38 0.36 0.50 0.34 0.14 0.34 
XLPN  -0.37 -0.35 -0.32 -0.30 -0.30 -0.34  0.33 0.12 0.35 0.30 0.24 0.08 0.18 -0.10 0.14 
XLPO  -0.51 -0.50 -0.44 -0.45 -0.43 -0.51  0.63 0.40 0.47 0.27 0.49 0.32 0.42 0.10 0.21 
XLAS  -0.38 -0.33 -0.39 -0.34 -0.35 -0.31  0.53 0.21 0.41 0.24 0.31 0.21 0.41 -0.05 0.27 
XLCH  -0.54 -0.53 -0.45 -0.35 -0.56 -0.55  0.71 0.46 0.58 0.40 0.51 0.41 0.52 -0.02 0.33 
XLAL  -0.28 -0.23 -0.25 -0.15 -0.23 -0.28  0.11 0.28 0.32 0.24 0.15 0.15 0.11 0.14 0.22 
 
Approximate 95% confidence intervals are as follows: 0.90 (0.85, 0.93);  0.80 (0.72, 0.86);  0.70 





Discriminant validity   
 
Sensitivity to disease stage   
 
The sensitivity of the scales to the large effects of moving from early (Stage I or II) disease to 
metastatic disease was tested with the HRQOL data at recruitment for the 113 patients whose 
disease did not progress contrasted with the HRQOL data from the last observation for the 45 
patients whose disease did progress.  Patients with newly diagnosed Stage I or II disease were 
expected to have much better HRQOL across all domains than patients with metastatic disease.  
 
Differences in the mean scores for the EORTC QLQ-C30 and EORTC QLQ-LC13 domain 
scales for patients with Stage I or II disease and patients with metastatic disease are illustrated in 
the box and whisper plot (Figure 8).  Mean differences and effect sizes are reported in Table 6. 
The mean differences for the scales were all in the expected direction, and, except for emotional 
functioning, were between 21.3 and 54.0, which is large relative to the scale range of 0-100.  All 
but one of the effect sizes was greater than one, which is large according to conventional 
guidelines. The emotional functioning scale had the smallest mean difference and effect size.  As 
the data was not normally distributed the non parametric Mann-Whitney U test was used to test 
the significance of differences for all domain scales and single items.  All scores were 
significantly different (Table 6).  For patients with metastases, functioning scores were all 
significantly lower and symptom scores were all significantly higher.    
8 
  
Figure 8.  Box and whisper plot showing differences in the mean scores for the EORTC QLQ-
C30 functioning and global health domain scales for patients with newly diagnosed Stage I or II 
disease (no metastases) at recruitment vs patients with metastatic disease at the last observation. 
    
                            



















Table 6.  Sensitivity of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to disease 
stage: Differences in mean scores, and effect sizes between patients with Stage I or II disease at 
recruitment (n = 112) vs patients with metastatic disease at the last observation (n = 45).   
 
Scale  Mean difference (CI)
a Effect size 
Physical functioning             38.3 (30.0, 46.7)***  1.89 
Role functioning             54.0 (44.0, 64.1)***  1.97 
Emotional functioning             13.7 (  5.1, 22..4)**  0.60 
Social functioning             45.3 (34.4, 56.2)***  1.72 
Cognitive functioning             27.9 (18.1, 37.7)***  1.29 
Global Health status/QOL             30.6 (22.9, 38.4)***  1.36 
Fatigue           -40.7 (-50.0, -31.3)***  1.77 
Nausea and Vomiting           -21.3 (-30.7, -12.0)***  1.14 
Pain           -39.6 (-50.2, -28.9)***  1.52 
Dyspnoea LC13           -35.6 (-45.0, -26.2)***  1.51 
a Positive differences indicate patients with stage I or II disease score higher on functioning 
scales and lower on   
  symptom scales. 
*P < 0.05; ** p < 0.01; ***p < 0.001 
 
 
Sensitivity to differences between asymptomatic to mildly symptomatic     
 
The sensitivity of the scales to the small effect of moving from asymptomatic to mildly 
symptomatic was tested with the HRQOL data at recruitment.  Patients who were asymptomatic 
at recruitment (ECOG score of 0) were expected to have slightly better HRQOL across all 
domains than patients who were symptomatic at recruitment but whose symptoms had little or 




Differences in the mean scores for the EORTC QLQ-C30 and EORTC QLQ-LC13 domain 
scales for patients with an ECOG score of 0 compared to those with an ECOG score of 1 are 
illustrated in the box and whisper plot (Figure 9).  Mean differences and effect sizes are reported 
in Table 7.  The mean differences (Table 7) for the scales were mostly in the expected direction 
(with the exception of the cognitive functioning and pain scales), and the largest was 7.2 points, 
which is small relative to the scale range of 0-100.  The effect sizes (Table 7) ranged from 0.05 
to 0.27, which is small according to conventional guidelines. The emotional functioning scale 
again had both the smallest mean difference and effect size.    
 
 
Figure 9.  Box and whisper plot showing the differences in mean scores for the EORTC QLQ-
C30 domain scales at recruitment for patients with ECOG 0 vs 1 vs 2 or 3.   
 
              






















Table 7.  Sensitivity of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to ECOG 
scores at recruitment: Differences in mean scores, and effect sizes between ECOG score 0 (n = 
55-56




c Effect size  Scale 
 3.9
 (-1.3,  9.2)  0.24  Physical functioning
 a, b
Role functioning    7.2 (-1.6, 16.1)  0.25 
Emotional functioning   1.2 (-7.0,  9.4)  0.05 
Social functioning    5.8 (-2.4, 14.0)  0.22 
Cognitive functioning           -3.7 (-10.3, 2.8)  0.20 
Global Health status/QOL    5.6 (-2.3, 13.5)  0.23 
Fatigue           -6.2 (-13.1, 0.6)  0.27 
Nausea and Vomiting           -1.0 ( -4.0,  2.0)  0.10 
Pain    2.1 (-5.8, 10.0)  0.09 
Dyspnoea LC13           -2.3 ( -9.2,  4.7)  0.10 
 
a Physical functioning (n=55),  Remainder (n=56);   
b Physical functioning (n=107), Remainder 
(n=106) 
c  Positive differences indicate patients with an ECOG score of 0, score higher on functioning 
scales and lower on         
   symptom scales. 





Differences in the mean scores for patients with ECOG scores of 0, 1, 2 and 3 were tested for 
statistical significance.  As the data was not normally distributed the non parametric ANOVA 
(Kruskal Wallis test) was used.  Significant differences were found only for the QLQ-C30 role 
functioning and emotional functioning scales (Fig 9), and the QLQ- LC13 single items coughing 
(Fig 10) and haemoptysis (Fig 11).  Patients with an ECOG  score of 2/3 had significantly lower 
role functioning  (χ
2  =  9.036  (df, 2), p = 0.011), and emotional functioning (χ
2  =  7.219  (df, 
2), p = 0.027) than patients with an ECOG score of 1 or 0.  Patients with an ECOG score of 0 
had significantly less coughing (χ
2  =  7.850  (df, 2), p = 0.020)  and haemoptysis (χ
2  =  12.147  
(df, 2), p = 0.002)  than patients with an ECOG score of 1 or 2/3.    
 
Figure 10.  Distribution of the EORTC QLQ-LC13              Figure 11.  Distribution of EORTC 
QLQ-LC13 single single item coughing at recruitment for patients                    item haemoptysis 
at recruitment for patients with                                             scores for ECOG 0 v 1 v 2/3                                   





























1 = Not at all; 2 = A bit; 3 = Quite a bit; 4 = Very much                   1 = Not at all; 2 = A bit; 3 = Quite a bit; 4 = Very much 
 
 
Sensitivity to age  
 
HRQOL data at recruitment was used to test the sensitivity of the domain scales to the small 
effect of age.  It was expected that the HRQOL of older patients would be lower than for 
younger patients for all physical domains but not psychosocial domains; 
  
Differences in mean scores for the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales 
for patients aged ≤ 60 years, 61-70 years and 70+ years, and effect sizes are reported in Table 8.   
The mean differences were mostly in the expected direction (with the exception of the symptom 
scales), but few were statistically significant.  The largest difference was 14.3 (social 
functioning) which is moderate relative to the scale range of 0-100, all other differences were 
below 9 which is small. All but two of the effect sizes were less than 0.30, which is small 
according to conventional guidelines.  The effect sizes for emotional functioning (0.35) and 
social functioning (0.46) were between small to modest by conventional standards.  As the data 
was not normally distributed the non parametric ANOVA (Kruskal Wallis test) was used to test 
the significance of differences for all domain scales and single items.  Only the QLQ-C30 social 
functioning scale and the single item, financial difficulties (Fig 13) discriminated between age 
groups.  Social functioning was significantly lower for the younger 60 years and under age group 
(χ
2 = 10.412  (df, 2), p = 0.005), and financial difficulty was significantly higher (χ
2  =  10.476  
(df, 2), p = 0.005).  The box and whisper plot (Fig 12) is a further illustration of the differences 




Table 8. Sensitivity of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to age at 
recruitment: Differences in mean scores, and effect sizes for ages ≤ 60 years (n=46-47
 a) vs 60-
70 years (n =59-63
 b) and 60-70 years vs 70+ years(n = 62-64
c). 
 
≤ 60 years vs 61 -70 years  61-70 years vs 70+ years   
Scale Mean  difference 
(CI)
d




Physical functioning        0.3 (-6.8,  7.4)  0.02        2.7 (-3.6, 9.0)  0.15 
Role functioning      -5.9 (-18.4, 6.7)  0.18      -3.4 (-13.1, 6.2)  0.12 
Emotional functioning      -1.5 (-11.5, 8.5)  0.06      -8.7 (-17.5, 0)  0.35 
Social functioning    -14.3 (-26.5, -2.2)  0.46      -3.6 (-11.6, 4.4)  0.16 
Cognitive functioning       5.5 (-1.8, 12.8)  0.27      -4.3 (-11.4, 2.8)  0.21 
Global Health status/QOL     -2.8 (-12.8, 7.3)  0.10      -2.3 (-11.1, 6.5)  0.09 
Fatigue       4.8 (-5.2, 14.9)  0.18       1.7 (-6.5, 9.8)  0.07 
Nausea and Vomiting       2.9 (-1.5, 7.3)  0.24       0.3 (-3.6, 4.2)  0.03 
Pain
       0.7 (-9.5, 10.8)  0.02       4.7 (-3.9, 13.3)  0.19 
Dyspnoea LC13     -1.7 (-10.7, 7.3)  0.07       4.7 (-3.5, 12.8)  0.20 
 
a Pain (n=46); Remainder (n=47)    
b Pain (n=59); Remainder (n=63)   
c Pain (n=62); Remainder 
(n=64) 
d Negative differences indicate that the function and HRQOL of older adults is worse than that of 
younger patients,   
   and that the symptom experience is better. 
*P < 0.05; ** p < 0.01; ***p < 0.001 
 
 
Figure 12.  Box and whisper plot showing differences in the mean scores for the EORTC QLQ-
C30 social functioning and nausea and vomiting domain scales at recruitment for age groups 
≤60yrs (n = 47
 )  vs  61-70yrs (n = 63
 )  vs  >70yrs (n = 64). 
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Figure 13.  Distribution of the EORTC QLQ-C30 single item financial difficulties at recruitment 
by ≤60yrs (n = 47)  vs  61-70yrs (n = 62)  vs  >70yrs (n = 64) 
 



















Sensitivity to gender  
 
The sensitivity of the scales to the small effect of gender was tested with the HRQOL data at 
recruitment.   It was expected that men would have a slighter better HRQOL (about 5 points) 
than women.  
 
The mean differences (Table 9) for the scales were mostly in the expected direction (with the 
exception of role functioning, pain and dyspnoea), and the largest was 7.1 points, which is small 
relative to the scale range of 0-100.  All but one of the effect sizes (Table 9) was less than 0.28, 
which is small according to conventional guidelines.  The cognitive functioning scale had the 
smallest mean difference and effect size.  As the data was not normally distributed, the non 
parametric Mann-Whitney U test was used to test the significance of differences for all domain 
scales and single items.  Only three scores discriminated between gender:  males scored 
significantly higher on the QLQ-C30 emotional functioning scale (Table 9) (z = -2.029, p = 
0.042) and significantly lower on the single item diarrhoea (Fig 16) (z = -2.407, p = 0.016);  
males scored significantly higher on the QLQ-LC13 single item coughing (Fig 15) (z = -3.384, p 
= 0.001).  The box and whisper plot (Fig 14) also illustrates the extent of the differences for the 





Table 9. Sensitivity of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to gender 
at recruitment: Differences in mean scores, and effect sizes between males (n = 124 -129
 a) and 
females (n = 44-45
 b). 
 
Scale  Mean difference (CI)
c Effect size 
Physical functioning  3.1 (-3.4, 9.6)  0.17 
Role functioning           -1.9 (-12.2, 8.4)  0.06 
Emotional functioning     7.1 (-1.1, 15.2)*  0.28 
Social functioning   2.6(-7.4, 12.7)  0.09 
Cognitive functioning  0.7 (-6.1, 7.4)  0.03 
Global Health status/QOL    1.2 (-7.7, 10.1)  0.05 
Fatigue           -0.9 (-9.4, 7.6)  0.04 
Nausea and Vomiting           -1.9 (-6.0, 2.2)  0.17 
Pain    3.0 (-4.2, 10.1)  0.12 
Dyspnoea LC13
,   3.4 (-4.3, 11.2)  0.15 
 
a  Dyspnoea (n=124); Pain (n=128); Remainder (n=129)   
b  Dyspnoea  (n=44);  Remainder 
(n=45) 
c  Positive differences indicate men score higher on functioning/QOL scales and lower on 
symptom scales. 
*P < 0.05 
 
 
Figure 14.  Box and whisper plot showing differences in the mean scores for the EORTC QLQ-
C30 emotional functioning and global health domain scales at recruitment by gender.   
 



















Figure 15.  Distribution of the EORTC QLQ-LC13                   Figure 16.  Distribution of the 
EORTC QLQ-C30  



























1 = Not at all; 2 = A bit; 3 = Quite a bit; 4 = Very much                       1 = Not at all; 2 = A bit; 3 = Quite a bit; 4 = Very much 
 
Sensitivity to comorbidities  
 
The sensitivity of the scales to the small effect of comorbidities was tested with the HRQOL data 
at recruitment.  It was expected that HRQOL would be inversely related to the number of 
comorbidities. 
 
Differences in mean scores for the EORTC QLQ-C30 and EORTC QLQ- LC13 domain scales 
for patients with none and one or more comorbidities, and effect sizes are reported in Table 10.   
The mean differences for the domain scales were mostly in the expected direction, and the 
largest was 12.5 points, which is moderate relative to the scale range of 0-100.  All but three of 
the effect sizes were less than 0.30, which is small according to conventional guidelines.  The 
effect sizes for cognitive functioning (0.32) and fatigue (0.36) were between small to modest, 
and for dyspnoea (0.57), modest by conventional standards.  As the data was not normally 
distributed, the non parametric Mann-Whitney U test was used to test the significance of 
differences for all domain scales and single items.  Only seven scores discriminated between 
comorbidities:  the QLQ-C30 physical functioning, cognitive functioning and fatigue scales 
(Table 10), and single items dyspnoea (Fig 18) and constipation (Fig 17); and the QLQ-LC13 
dyspnoea scale (Table 10, Fig 20) and single item peripheral neuropathy (Fig 19).  Patients with 
comorbidities had significantly worse physical (z = -2.481, p = 0.013) and cognitive (z = -2.068, 
p = 0.039) functioning, and significantly more fatigue (z = -2.107,  p = 0.035), dyspnoea (QLQ-
C30: z = -2.448, p = 0.014,  QLQ-LC13:  z = -3.676, p = 0.000), constipation (z = -3.818, p = 
0.000) and peripheral neuropathy (z = -2.039,  p = 0.041). 
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Table 10.  Sensitivity of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to 
comorbidities at recruitment: Differences in mean scores, and effect sizes between patients with 
None (n = 86-90
 a) vs 1 or more (n = 82-84
b). 
 
Scale  Mean difference (CI)
c Effect size 
Physical functioning    5.3 (-0.1, 10.7)*  0.29 
Role functioning  5.7 (-3.3, 14.6)  0.19 
Emotional functioning  5.7 (-1.7, 13.2)  0.23 
Social functioning  5.2 (-3.0, 13.4)  0.19 
Cognitive functioning           6.3 (0.5, 12.2)*  0.32 
Global Health status/QOL  6.0 (-1.5, 13.5)  0.24 
Fatigue          -8.6 (-15.7, 1.4)*  0.36 
Nausea and Vomiting          -2.5 (-5.8, 0.9)  0.22 
Pain          -4.2 (-11.6, 3.2)  0.17 
Dyspnoea LC13
        -12.5 (-19.1, -5.9)**  0.57 
 
a  Dyspnoea (n=86); Pain (n=89);  Remainder (n=90)      
b  Dyspnoea (n=82);  Remainder (n=84) 
c Positive differences indicate people with no comorbidities at recruitment score higher on 
functioning/QOL scales   
  and lower on symptom scales. 
*P < 0.05;  ** p < 0.001 
 
Figure 17.  Distribution of the EORTC QLQ-C30               Figure 18.  Distribution of the 
EORTC QLQ-C30   
single item constipation scores by comorbidities                 single item dyspnoea scores by 
































Figure 19.  Distribution of the EORTC QLQ-LC13            Figure 20.  Distribution of the 
EORTC QLQ-LC13   
single item peripheral neuropathy scores by comorbidities        dyspnoea domain scale scores by 
































1 = Not at all; 2 = A bit; 3 = Quite a bit; 4 = Very much                 Note: scale goes from 00 to 100 in 9 stteps 





Internal consistency and Test-re-test reliability 
 
The reliability statistics for the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales are 
reported in Table 11.  The Cronbach's alpha values for the domain scales were generally good to 
excellent, with the exception of the cognitive functioning and nausea scales.  The intra-class 
correlation coefficients (ICC) were somewhat lower, but still generally acceptable to good (0.70 
to 0.81) with the exception of the nausea (0.42) and pain (0.56) scales.  Generally, this evidence 
supported the reliability of the scales of both instruments. 
 
 
Table 11.  Reliability of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales:  Internal 
consistency and test re-test statistics from HRQOL data taken at recruitment (n = 174) and 
recruitment vs admission to hospital (n = 132) respectively.  
 
Scale Cronbachs  alpha  Intra-class 
coefficients 
Physical functioning  .87  .81 
Role functioning  .94  .74 
Emotional functioning  .90  .78 
Social functioning  .86  .70 
Cognitive functioning  .68  .70 
Global Health status/QOL  .94  .77 
Fatigue .91  .72 
Nausea and Vomiting  .67  .42 
Pain .87  .56 
Dyspnoea LC13  .89  .76 





It is also useful to look at the mean change in the test-retest data (Table 12), as this suggests the 
degree of change that may be expected by chance for each scale.  The mean differences ranged 
from 0.4 to -2.6 which is very small relative to the scale range of 0-100.  All but two of the effect 
sizes were less than 0.10 which is very small according to conventional guidelines.  A paired 
sample t-test, conducted to test the significance of the differences, showed that none were 
statistically significant.  
 
 
Table 12.  Test-retest reliability of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain 




Scale  Mean difference (CI)  Effect size 
Physical functioning  0.5 (-3.5, 4.6)  0.03 
Role functioning  1.2 (-5.5, 7.9)  0.04 
Emotional functioning  0.6 (-5.2, 6.4)  0.03 
Social functioning  -2.6 (-8.7, 3.4)  0.10 
Cognitive functioning  0.4 (-3.7, 4.6)  0.02 
Global Health status/QOL  0.4 (-5.2, 6.0)  0.02 
Fatigue  -1.1 (-6.2, 3.9)  0.05 
Nausea and Vomiting  -1.0 (-3.2, 1.2)  0.11 
Pain  0.8 (-4.2, 5.8)  0.04 
Dyspnoea LC13  1.4 (-3.9, 6.7)  0.07 
 
a Recruitment: Dyspnoea (n=126); Physical functioning (n = 132);  Remainder (n=132) 




Responsiveness to the effects of surgery 
 
Responsiveness to the clinical effects of surgery was tested by comparing the HRQOL 
assessment scores at admission and discharge, of those who completed questionnaires at both 
these time points.  A clinically large effect was expected, that is function symptoms and QOL 
were all expected to be worse at discharge, and this negative impact was expected to be large. 
 
Differences in mean scores for the EORTC QLQ-C30 and EORTC QLQ- LC13 domain scales 
from admission to discharge, and effect sizes are reported in Table 13.  The mean differences for 
the domain scales were all in the expected direction, and with the exception of emotional 
functioning, ranged from 14.5 to 53.9, which is large relative to the scale range of 0-100.  All but 
one of the effect sizes were greater than 0.8, which is large according to conventional guidelines.  
The emotional functional scale had the smallest mean difference (5.8) and effect size (0.23).  A 
paired sample t-test, conducted to test the significance of the differences, showed that all were 





Table 13.   Responsiveness of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to the 




c Scale  Effect size 
Physical functioning       -31.4 (-35.7, -27.0)***  1.51 
Role functioning       -53.9 (-60.5, -47.3)***  1.77 
Emotional functioning         -5.8 (-9.7, -1.9)**  0.23 
Social functioning       -37.2 (-43.2, -31.2)***  1.20 
Cognitive functioning       -19.6 (-23.7, -15.6)***  0.80 
Global Health status/QOL       -26.6 (-31.2, -22.0)***  1.13 
Fatigue         38.6 (33.8, 43.3)***  1.60 
Nausea and Vomiting         14.5 (10.9, 18.2)***  0.83 
Pain         47.5 (41.8, 53.2)***  1.76 
Dyspnoea LC13         19.6 (14.5, 24.7)***  0.78 
 
a  Admission:  Physical and Role functioning, Global health status, Pain, Dyspnoea (n=136);  
Remainder (n-137) 
b  Discharge:  Role and emotional functioning, Global health status, Nausea and vomiting 
(n=136);  
                       Dyspnoea (n-122); Remainder (n=137). 
c Negative differences indicate deterioration in function/QOL over time and improvement in 
symptoms. 
*P < 0.05; ** p < 0.01; ***p < 0.001 
 
Responsiveness to disease progression  
 
Responsiveness to disease progression was tested by comparing the HRQOL assessment scores 
at recruitment with those from the first and the last assessment following a diagnosis of disease 
recurrence, for the patients whose disease progressed within the study period and who completed 
questionnaires at each of these time points.  A clinically large effect was expected, with 
functioning and QOL deteriorating and symptom experience increasing over time.    
 
Differences in mean scores for the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales 
from recruitment to the first and last observation following recurrence, and effect sizes are 
reported in Table 14.  When comparing the differences from recruitment to the first observation 
following recurrence, the mean differences for all the domain scales were in the expected 
direction, and all but one ranged from 15.8 to 31.5, which is large relative to the scale range of 
0-100.  Four of the effect sizes were greater than 0.8 which is large according to conventional 
guidelines.  The remainder, with the exception of emotional functioning, ranged from 0.53 to 
0.75 which is moderate.  The emotional functioning scale was the only one with a small mean 
difference (4.6) and effect size (0.15).  A paired sample t-test, conducted to test the significance 
of the differences, showed that, with the exception of emotional functioning, all were statistically 
significant.  The differences and effect sizes continued to grow over time. Comparing 
recruitment to the last observation following a diagnosis of recurrence, the differences were all 
larger than at the first observation following metastases.  All of the effect sizes except for 
emotional functioning were now large (over 0.8).  The effect size for emotional functioning was 
still small (0.19).  Paired sample t-tests showed that all differences, except for emotional 





Table 14.   Responsiveness of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to 
the effects of disease progression: changes in mean scores, and effect sizes from recruitment to 
first and last observation after metastases (n = 33-37
 a, b) 
 
  Recruitment to first observation 
following metastases 
Recruitment to last observation 
following metastases 
Mean difference (CI)
 c Effect size  Mean difference (CI)
 c Scale  Effect size 
Physical functioning   -30.7 (-40.2, -21.1)***  1.40   -41.4 (-51.5, -31.4)***  1.89 
Role functioning   -31.5 (-44.3, -18.8)***  0.97   -41.0 (-54.9, -27.1)***  1.28 
Emotional functioning     -4.6 (-14.9, 5.7)  0.15     -5.5 (-16.2, 5.3)  0.19 
Social functioning   -23.0 (-35.3, -10.7)**  0.67   -32.0 (-43.9, -20.0)***  0.96 
Cognitive functioning   -15.8 (-28.5, -3.1)**  0.53   -25.2 (-36.2, -14.2)***  0.82 
Global Health status/QOL   -18.5 (-28.2, -8.8)***  0.67   -21.6 (-32.0, -11.3)***  0.84 
Fatigue     22.2 (11.9, 32.5)***  0.75    33.9 (23.9, 44.0)***  1.17 
Nausea and Vomiting     20.3 (10.5, 30.1)***  0.86    23.4 (13.2, 33.6)***  0.94 
Pain     31.5 (21.1, 41.8)***  1.10    39.3 (28.1, 50.6)***  1.33 
Dyspnoea LC13     20.4 (9.7, 31.1)***  0.72     
Dyspnoea LC13                     31.6 (20.8, 42.4)***  1.11 
 
a  Recruitment and First observation: Dyspnoea (n=33); Remainder (n=37)    
b Last observation:  Dyspnoea (n=35); Remainder (n=37) 
c Negative differences indicate deterioration in function/QOL over time and improvement in 
symptoms. 
*p < 0.05; ** p < 0.01; ***p < 0.001;   
All scales except for emotional functioning are significant from recruitment to last observation 
*** p < 0.001  
 
 
Responsiveness to the effects of radiotherapy 
 
Responsiveness to the clinical effects of radiotherapy was tested by comparing the HRQOL 
assessment scores at recruitment with those from the first and the last radiotherapy treatment, for 
the patients who had radiotherapy and who completed questionnaires at each of these time 
points.  A clinically moderate to large effect was expected in the short term, with radiotherapy 
having a deleterious impact on all domains of QOL.   Differences in mean scores for the EORTC 
QLQ-C30 and EORTC QLQ-LC13 domain scales from recruitment to the first and last 
radiotherapy treatments, and effect sizes are reported in Table 15.   
 
Comparing the differences from recruitment to the first radiotherapy treatment, the mean 
differences for the domain scales were mostly in the expected direction (except for emotional 
and cognitive functioning).  The majority of the differences were moderate (9.1 to 13.8 and 15.3 
for role functioning) relative to the scale range of 0-100.  Cognitive functioning, global health 
nausea and vomiting were trivial to small (1.8 to 4.6).  Only two of the effect sizes were large 
(physical and role functioning at 0.99 and 1.01), the remainder were small to moderate (0.09 to 
0.67) according to conventional guidelines.  Cognitive functioning had the smallest mean 
difference (1.8) and effect size (0.09).  A paired sample t-test, conducted to test the significance 
of the differences, showed that physical, role and social functioning, fatigue, pain and dyspnoea 




Comparing the first to last radiotherapy treatment, differences were again mostly in the expected 
direction and most with a further small to moderate (6.5 to 9.3) difference.  Most of the effect 
sizes were small (0.19 to 0.39).  Physical functioning had the smallest mean difference 
(0.02).and effect size (0.00).  A paired sample t-test, conducted to test the significance of the 
differences, showed that social functioning, global health status and fatigue were statistically 
significant.   
 
Differences from recruitment to the last radiotherapy treatment were all in the expected direction 
and mostly moderate to large (8.8 to 22.2).  Effect sizes were mostly moderate (0.49 to 0.74) to 
large (0.87).  The effect sizes for emotional and cognitive functioning and global health were 
only trivial or small. Cognitive functioning again had the smallest mean difference and effect 
size.  Significance testing showed that, as for recruitment to first radiotherapy treatment, the 
mean differences for physical, role and social functioning and fatigue, pain and dyspnoea were 
significantly different.   
 
 
Table 15.  Responsiveness of the EORTC QLQ-C30 and EORTC QLQ-LC13 domain scales to 
the effects of adjuvant radiotherapy: changes in mean score from Recruitment to First and Last 
radiotherapy treatments (n = 30-36
a ) 
 
  Recruitment to first 
radiotherapy treatment 
First to last 
radiotherapy treatment 
Recruitment to last 
radiotherapy treatment 
Scale  Mean difference (CI)








Physical functioning   -13.8 (-18.9, -8.7)***  0.99        0.02 (-5.6, 5.7)  0.00    -13.8 (-20.5, -7.1)***  0.87 
Role functioning   -15.3 (-27.8, -2.7)*  1.01      -6.9 (-16.4, 2.5)  0.22    -22.2 (-36.2, -8.3)*  0.72 
Emotional functioning      9.1 (-0.2, 18.4)  0.37      -1.8 (-5.5, 1.8)  0.08        7.3 (-3.1, 17.6)  0.28 
Social functioning   -11.1 (-21.5, -0.8)*  0.45      -9.3 (-17.9, -0.6)*  0.32    -20.4 (-33.2, -7.6)*  0.69 
Cognitive functioning      1.8 (-7.6, 11.3)  0.09      -3.2 (-7.2, 0.8,)  0.19      -1.4 (-11.9, 9.2)  0.06 
Global Health status/QOL    -4.6 (-13.8, 4.5)  0.21      -6.5 (-12.2, -0.8)*  0.32    -11.1 (-21.0, -1.2)  0.49 
Fatigue      9.9 (1.3, 18.4)*  0.47        6.6 (0.4, 12.8)*  0.31      16.5 (6.7, 26.3)*  0.73 
Nausea and Vomiting      2.3 (-2.6, 7.2)  0.21        6.5 (-0.3, 13.3)  0.39        8.8 (-1.9, 15.7)  0.57 
Pain    13.3 (4.2, 22.4)**  0.67        1.9 (-5.1, 8.8)  0.09      15.2 (5.4, 25.1)**  0.74 
  10.0 (3.7, 16.3)**  0.53 
      4.1 (-2.6, 
10.7) 0.19 
    14.1 (7.4, 
20.7)***  0.68 
Dyspnoea LC13 
a  Dyspnoea (n=30); Pain (n=35); Remainder (n=36) 
c  Negative differences indicate deterioration in function/QOL over time and improvement in 
symptoms 






Health related quality of life (HRQOL) is an important component of the evaluation of 
treatment, particularly in chronic diseases where the aim of treatment is to ameliorate symptoms 
rather than extend survival. The assessment of HRQOL in cancer care is particularly important 
because the physical and psychological effects of the disease, and the benefits and toxicities of 
cancer treatments have a direct effect on patients’ wellbeing and their ability to perform their 
usual roles and abilities (Schipper and Clinch 1988; Fallowfield 1990; Cella and Tulsky 1993b; 
Cleton 1995; Greco 1995; Hanks and Hoskin 1995; Maguire 1995; Steel 1995).   
 
The Quality of Life Questionnaire Core module (QLQ-C30) (Aaronson, Ahmedzai et al. 1993) is 
the most widely used instrument for measuring HRQOL in clinical trials.  It is the core 
component of the European Organisation for Research and Treatment of Cancer (EORTC)’s 
modular approach to QOL assessment and represents QOL domains relevant across a wide range 
of cancer sites and treatment types.  The QLQ-C30 is complemented by modules specific to 
particular cancers such as the lung cancer module (QLC-LC13) which is meant for use with a 
wide variety of lung cancer patients in varying disease stage and treatment modality (Bergman, 
Aaronson et al. 1994).  Both the QLQ-C30 and the QLQ-LC13 have been previously validated.  
A bibliography of validation studies for the QLQ-C30 can be found in the EORTC QLQ-C30 
scoring manual (Fayers, Aaronson et al. 2001) and a summary of findings from numerous 
studies can be found in Spilker et al (Spilker 1996).  The QLQ-LC13 was validated in field tests 
together with the QLQ-C30 (Bergman, Aaronson et al. 1994), and has subsequently been 
validated in other studies (Chie, Yang et al. 2004; Nowak, Stockler et al. 2004).    
 
However the validity of a HRQOL instrument is not something that is established by a single or 
even a few studies.  Whether or not the instrument produces sensible and useful results in 
various circumstances should be judged in an ongoing process of validation (Streiner and 
Norman 1996; Fayers and Machin 2000).  Although the QLQ-C30 and the QLQ-LC13 have 
undergone a continual process of validation across a range of health care contexts and disease 
groups, and in different nationalities and cultures, our confidence in, and understanding of, the 
instruments will develop as the body of evidence accrues.  The results from this study contribute 
to the growing literature supporting the scientific validity, reliability and responsiveness of the 
QLQ-C30 and QLQ-LC13 as effective measures of HRQOL in the area of cancer care, and, 
more specifically, as measures of HRQOL in an Australian sample of people with early stage 
non-small cell lung cancer (NSCLC).   
  
The factor structure reported previously for the QLQ-C30 (Aaronson, Ahmedzai et al. 1993) and 
the QLQ-LC13 (Bergman, Aaronson et al. 1994) was generally replicated in this sample, 
confirming the questionnaires’ construct validity.  Confirmatory factor analysis (CFA) 
conducted on the physical functioning scale of the QLQ-C30 showed that all measures were 
either adequate or better.  Factor loadings for four of the five items ranged from 0.51 to 0.95, 
goodness of fit indices were adequate and internal consistency was good (0.88).  CFA on the 
emotional functioning scale suggested an excellent fit.  Factor loadings were all above 0.80,  
goodness of fit indices were excellent as was internal consistency (0.90).   Internal consistency 
for the two and three item scales ranged from acceptable to excellent.  For the QLQ-LC13 
dyspnoea scale, factor loadings were acceptable (0.58 – 0.93) and internal consistency was good 
(0.89).  When these measurement models were included in the structural models our findings 
were however mixed.  For the QLQ-C30 model (multi-items scores only),  factor loadings were 
good (0.67 to 0.91) but fit indices varied from poor to good.   For the QLQ-LC-13 model 
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(without sore mouth and alopecia which were taken out to improve the model) factor loadings 
varied from poor  to good (0.26 – 0.73) but indices of fit measures were generally adequate.  
However, consideration of clinical validity probably outweigh such psychometric concerns in 
this context.  Given that the QLQ-C30 is well established and widely used in its current form, 
the results of this study are unlikely to lead to modifications of the instrument. 
 
Our study also confirmed the convergent and divergent validity of the instruments. We expected 
moderate correlations among the physical-based functioning scales and symptoms scales, and 
among the psychosocial scales.  The results were generally in agreement with our expectations 
although correlations tended to be strong rather than moderate.  For the QLQ-C30, more than 
50% of the correlations among the physical-based functioning scales and symptom scales were 
strong (0.50 to 0.81) and approximately 25% were moderate (0.31 to 0.47).  All correlations 
among the psychosocial scales were strong (0.54 to 0.66).  This is in line with numerous other 
studies that also found strong correlations among these scales, particularly between the physical, 
role fatigue and pain scales. However, contrary to expectations we found strong correlations 
among the physical and psychosocial scales (0.52 to 0.80).  While most previous studies found 
small correlations among these scales, there were several studies that had similar results to ours.  
Some (Osoba, Zee et al. 1994; Blazeby, Conroy et al. 2003; Cocks, Cohen et al. 2007) found 
moderate to large correlations between the emotional functioning and physical functioning, role 
functioning and nausea and vomiting scales.  Moderate to large correlations between the 
emotional functioning and fatigue and pain scales were also found (Aaronson, Ahmedzai et al. 
1993; Osoba, Zee et al. 1994; Kaasa, Bjordal et al. 1995; Fitzsimmons, Kahl et al. 2005; Cocks, 
Cohen et al. 2007).  While correlations among the QLQ-LC13 symptom scales and single items 
were also generally consistent with our expectation we did find slightly more small (42%) than 
moderate (40%) correlations.   
 
Correlations among scales and single items of the QLQ-C30 and QLQ-LC13 were also generally 
consistent with expectations (50% of correlations between scales and items were moderate and 
50% correlations between scales only were strong).  A strong correlation between the dsypnoea 
scale on the QLQ-LC13 and the dyspnoea item on the the QLQ-C30 was also found in a 
previous study (Chie, Chang et al. 2003).  However, as for correlations within each of the 
individual instruments, correlations between the physical and psychological scales and items of 
the two instruments were contrary to our expectations with more than 60% being moderate and 
those among the scales even higher (0.50 to 0.67). 
 
The sensitivity of the scales to the expected effects of progressive disease, age, gender, and 
comorbidities, provide further support for the questionnaires’ discriminant validity.  In terms of 
moving to metastatic disease, differences in the QLQ-C30 scale scores were all in the expected 
direction and, except for emotional functioning, were large (21.3 to 54.0) and significant, as 
were the effect sizes (1.14 to 1.97).  Although the effect size for emotional functioning was 
moderate (0.60), the differences were statistically significant.  These results generally confirm 
findings from other studies evaluating differences in quality of life for patients with local disease 
compared to those with metastatic disease (Aaronson, Ahmedzai et al. 1993; Osoba, Zee et al. 
1994).   In relation to the QLQ-LC13 however, our findings were contrary to previous studies 
that found no significant difference in scores on the dyspnoea scale for local and metastatic 
disease patients (Bergman, Aaronson et al. 1994; Nicklasson and Bergman 2007).  They did 
however find significant differences for the single items coughing and haemoptysis which we 




In terms differences between asymptomatic (ECOG 0) and symptomatic but completely 
ambulant (ECOG 1) disease, our study revealed small differences in scores and effect sizes as 
expected, indicating that both instruments are sensitive to this small effect.  For the QLQ-C30, 
the largest difference was 7.2 for role functioning and the smallest was 1.2 for emotional 
functioning.  Differences for the cognitive functioning and pain scales were however not in the 
expected direction. This is understandable for cognitive functioning, as it is not easily observed 
(by the person rating the ECOG status of the patient) and is not usually considered a symptom 
per se.  It is less understandable for pain, since this is a common symptom in cancer, but perhaps 
not in fully ambulant lung cancer patients.  The mean difference for the QLQ-LC13 dyspnoea 
scale was -2.3.  It is difficult to compare our results here to other studies as most either compare 
differences across all, or combinations of,  ECOG levels (Bergman, Aaronson et al. 1994; 
Osoba, Zee et al. 1994; McLachlan, Devins et al. 1998; Brabo, Paschoal et al. 2006), or use 
different criteria to measure performance status such as the World Health Organisation WHO 
(Nicklasson and Bergman 2007) or Karnoffsky Performance Status (KPS) (Bjordal, de Graeff et 
al. 2000).  These studies did however find the instruments were able to detect a difference in 
performance status by disease stage.  Our study showed that they were not only able to detect 
differences, but to detect differences in the smallest change in disease status, namely moving 
from asymptomatic (ECOG 0) to mildly symptomatic (ECOG 1) disease.   
 
Our findings in relation to age, gender and comorbidity reflect findings from other studies, 
though these are limited.  For the QLQ-C30 we found that for several scale, mean scores 
deteriorated as age increased. Most of these differences were small to moderate, as expected, 
except for social functioning which was large, especially for ages under 60 years compared to 
71-70 years.  Role functioning had the second largest difference although this was classified as a 
moderate change.  Lund Hagelein et al (2006) found the same trend and, as in our study, the 
largest differences were in the social functioning scale followed by role functioning.  They 
however, found that scores on the emotional functioning scale improved with age which was 
contrary to our findings.  Contrary to expectation, our study found that scores on the symptom 
scales improved slightly (though not significantly) with age.  This trend was also found to some 
degree in the study by Lund Hagelin et al (2006). It is not clear why this should be the case, but 
perhaps older patients are more accepting of poorer health generally due ot the loss of health that 
occurs with aging, and that this enhances their ability to cope and therefore reduces their 
perception of the degree of symptoms, which in turn influences their self-report of their 
symptom experience. 
 
The differences we found in scores for gender were small as expected and mostly in the expected 
direction. Mean differences and effect sizes were small (largest difference was 7.1 for QLQ-C30 
emotional functioning and smallest was 0.7 for QLQ-C30 cognitive functioning).  Only a few 
differences were statistically significant. Males scored significantly higher on the QLQ-C30 
emotional functioning scale and significantly lower on the single item diarrhoea;  males scored 
significantly higher on the QLQ-LC13 single item coughing.  Small though non significant 
differences in scale scores for the QLQ-C30 were also found in a sample of patients with 
pancreatic cancer (Fitzsimmons, Kahl et al. 2005) and also in a study of terminally ill cancer 
patients (Lundh Hagelin, Seiger et al. 2006).  That study however found that women had 
significantly higher scores for nausea and vomiting whereas in our study scores were higher for 
women but they were not significant.   
 
In terms of sensitivity to comorbidities, mean differences for the domain scales were mostly in 
the expected direction, and were small to moderate. The largest was for the QLQ-LC13, 
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Dyspnoea, which had a difference of 12.5 points.  Differences for the QLQ-C30 physical 
functioning, cognitive functioning and fatigue scales and single items constipation and 
dyspnoea, and the QLQ-LC13 dyspnoea scale and single item peripheral neuropathy, were 
statistically significant.  We only found one other study ((Michelson, Bolund et al. 2000) that 
had investigated the instruments sensitivity in relation to comorbidities. The sample in this study 
did not consist of cancer patients but rather a random sample of individuals with chronic health 
problems including cancer.  Their results also showed that the QLQ-C30 was able to 
discriminate between people with differing levels of comorbidities.   
 
When evaluating the sensitivity of the instruments to the small effects of moving from 
asymptomatic to mildly symptomatic disease, age, gender and comorbidities it should be 
remembered that while differences are small and may not be significantly different these 
differences may still be clinically relevant (King 1996).  For the QLQ-C30 a difference of 5 
points (or 10 for role functioning) is relatively small but may be clinically important.  For the 
emotional and cognitive functioning scales and for the QLQ-LC13 dyspnoea scale, there is 
insufficient evidence to date to judge the amount of difference required for clinical relevance.  In 
our study all small effects were detected by the QLQ-C30 and the QLQ-LC13.  Although the 
differences were small, in many cases they were clinically relevant.  
 
The reliability of both instruments was also confirmed in this sample. The Cronbach's alpha 
values for the domain scales of both the QLQ-C30 and QLQ-LC13 were generally excellent 
(0.86 to 0.94), with the exception of the cognitive functioning (0.68)  and nausea (0.67) scales.   
For the QLQ-C30, our cronbachs alphas were generally higher than those in earlier validation 
studies but similar to those in more recent studies that used the revised version (version 
3)(Aaronson, Ahmedzai et al. 1993; Ringdal and Ringdal 1993; Fossa 1994)  (Osoba, Zee et al. 
1994; Kaasa, Bjordal et al. 1995; Ringdal, Ringdal et al. 1999; Bjordal, de Graeff et al. 2000; 
Martin, Rubenstein et al. 2003; Nowak, Stockler et al. 2004)  (Galalae, Loch et al. 2004; 
Fitzsimmons, Kahl et al. 2005; Galalae, Michel et al. 2005; Luo, Fones et al. 2005; Poveda, 
Lopez-Pousa et al. 2005; Boehmer and Luszczynska 2006; Easson, Bezjak et al. 2007)  (see 
Appendix, Table A1).  The cognitive functioning scale, as it did in all previous studies, had the 
lowest  cronbach’s alpha.  Our role functioning scale had the highest cronbach’s alpha.  This is 
not surprising as despite earlier studies reporting low alphas for this scale, more recent studies, 
using version 3, all report high alphas.  The cronbach’s alpha for the QLQ-LC13 is also similar 
to those reported in previous studies (Bergman, Aaronson et al. 1994; Chie, Yang et al. 2004; 
Brabo, Paschoal et al. 2006; Nicklasson and Bergman 2007) (see appendix) .  The intra-class 
correlation coefficients (ICC) were somewhat lower than the cronbach’s alphas, but still 
generally acceptable to good (0.70 to 0.81) with the exception of the nausea (0.42) and pain 
(0.56) scales.  Low ICC’s  for the nausea and pain scales were also found in previous studies 
(Martin, Rubenstein et al. 2003; Chie, Yang et al. 2004). The distributions of the nausea and pain 
scales are usually skewed ,with the majority of scores at the low end of the scale (floor effects) 
(Fayers, Weeden et al. 1998). The low ICC scores for these scales are as much a refection o the 
low variability in scores among people as large mean change over a period when change should 
not occur (ie, poor reliability). This is one of the limitations of the ICC as a measure of 
reliability. This is why we also assessed reliability through the mean differences from the test-
retest data.  Differences ranged from 0.4 to -2.6, which is very small and t-tests showed that 
none of the differences were statistically significant, confirming the reliability of all the scales.  
 
The responsiveness of most scales of the QLQ-C30 and the QLQ-LC13 to the large effects of 
surgery and radiotherapy and to disease recurrence support the instruments’ longitudinal validity 
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in this sample.  In terms of surgery, with the exception of the emotional functioning scale (5.8, 
0.23), mean differences and effect sizes for all QLQ-C30 scales were large (14.5, 0.83 for nausea 
and vomiting to 53.9, 1.77 for role functioning) and significant.  These large differences are 
similar to those found in studies of patients with colorectal liver metastases who underwent 
surgery (Krabbe, Peerenboom et al. 2004).  Other studies of patients with head and neck cancer 
(Bjordal, de Graeff et al. 2000) and prostate cancer (Krahn, Bremner et al. 2007) found small to 
moderate differences as a result of treatment.  In these two studies treatment types were 
combined and included surgery, radiotherapy, hormone therapy, chemotherapy, or combinations 
of these.  The dyspnoea scale of the QLQ-LC13 was also found to be responsive to the effects of 
surgery with a mean difference and effects size of  19.6 and 0.78.   
 
In relation to radiotherapy, in this sample, mean differences from recruitment to the first 
radiotherapy were mostly moderate (9.1 to 13.8 and 15.3 for role functioning; ) and effect sizes 
ranged mostly from small to moderate (0.09 to 0.67) with only physical and role functioning at 
0.99 and 1.01 being large.  By the last radiotherapy treatment, mean differences were mostly 
moderate to large (8.8 to 22.2) and effect sizes were mostly moderate to large (0.49 to 0.87).  
Significance testing showed that differences for the QLQ-C30 physical, role and social 
functioning, fatigue, and pain scales and the QLQ-LC13 dyspnoea scale were statistically 
significant, that is, patients experienced significant deterioration in physical, role and social 
functioning and increased fatigue pain and dyspnoea.  These findings add to the current evidence 
available in the literature.  Studies of patients with prostate cancer reported significant 
differences in QLQ-C30 scores, as a result of radiotherapy  treatment.  Results from one study 
(Rodrigues, Bezjak et al. 2004) indicated patients  experienced  significant worsening of fatigue, 
pain and a deterioration in global health, and another study indicated a significant deterioration 
in role functioning and increased fatigue (Janda, Gerstner et al. 2000).   Kaasa et al (Kaasa, 
Bjordal et al. 1995) in a study with a heterogenous sample of patients with advanced disease 
treated with palliative radiotherapy also found significant differences for the physical and role 
functioning scale and the fatigue scale indicating a deterioration in physical and role functioning 
and increase in fatigue in this sample.  Studies evaluating the QLQ-C30, in which treatment 
modalities were combined (ie radiotherapy, surgery, hormone therapy, chemotherapy, or 
combinations of these), also found differences.  Aaronson et al (Aaronson, Ahmedzai et al. 
1993), in a heterogenous sample of cancer patients, found that for patients whose performance 
status (as measured by ECOG scores) deteriorated, physical and role functioning and global 
health deteriorated significantly, and symptoms of fatigue, and nausea and vomiting increased as 
a result of radiotherapy.  Bjordal et al (Bjordal, de Graeff et al. 2000)  in their head and neck 
cancer sample found that all scales except for the emotional functioning scales were significantly 
different with patients’ functioning deteriorating and symptoms worsening, and Krahn et al 
(Krahn, Bremner et al. 2007)  in a prostate cancer sample found small to moderate effect sizes 
for the physical, role, emotional and social functioning scales showing a deterioration in 
functioning on these scales.   
 
 The instruments were also responsive to the effects of disease recurrence.  From recruitment to 
the first assessment following a diagnosis of disease recurrence, with the exception of the 
emotional functioning scale, all mean differences were large (15.8 to 31.5) and effect sizes were 
moderate to large (0.53 to 1.4).  By the last assessment following recurrences mean differences 
had continued to grow and all effects sizes except for the emotional functioning scale were large.  
For the emotional functioning scale the instruments did pick up differences but these were much 
smaller (mean difference and effect size of 5.5 and 0.19 respectively) by the last observation 
following recurrence.  Our findings add to those of  Bjordal et al (Bjordal, de Graeff et al. 2000) 
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who, in their study of head and neck cancer patients, also found statistically and clinically 
significant differences in scores on the QLQ-C30 role, emotional, and social functioning and 
fatigue and pain scales between patients who had been newly diagnosed and those with a 
diagnosis of recurrent disease.  The QLQ-LC13 dyspnoea scale was also found to be responsive 
to the effects of disease recurrence with a mean difference and effect size of 20.4 and 0.72 at 
first observation post recurrence and 31.l6 and 1.11 at last observation.   
 
A limitation of our study was that we focussed predominately on the multi item scales of the 
instruments, with limited analysis of the single items.  This restricted our findings and 
comparisons to other validation studies.  However, we did conduct an extensive array of 
analyses on the scales to determine validity reliability and responsiveness and as such are 




The results of this study confirm that the EORTC QLQ-C30 and the EORTC QLQ-LC13 are 
valid, reliable and responsive measures of HRQOL in Australians with early stage non-small cell 
lung cancer.   They also add to the already large body of evidence supporting the validity, 
reliability and responsiveness of the QLQ-C30 as an effective HRQOL measure for a range of 
cancers, and add to the growing evidence for the QLQ-LC13.  In addition, by utilizing data from 
an existing RCT study in which to conduct this validation study, we have provided an illustration 
of “validation by application”.  This is a way to not only add value to HRQOL data collected for 
other purposes, but perhaps more importantly, to contribute to collective knowledge about the 
measurement properties and interpretability of HRQOL instruments, particularly in Australian 



















Table A1: Cronbach’s α values for the EORTC QLQ-C30 and the EORTC QLQ-LC13 in 





   PF RF CF EF SF  Global  Fatigue  NV  Pain  Dyspnoea 









0.75 0.55 0.65 0.85 0.72 0.83  -  0.84 0.86   
Bergman et al  Lung            0.81 
1994 
Fossa et al 1994  Breast  0.61  0.53  0.69 0.75 0.72 0.91  0.83 0.84 0.85   




0.68 0.54 0.56 0.73 0.68 0.86 0.80 0.65  0.82   
Kaasa et al 1995  Hetero-
genous 
0.77 0.68 0.62 0.80 0.78 0.88 0.87 0.81  0.89   




- 0.69 -  -  - 0.83  -  -  -   
Ringdal et al 
1999 
  0.77 0.63 0.64 0.83 0.76 0.89 0.88 0.77 0.89   




0.84 -  -  -  -  -  -  -  -   




0.78 0.59 0.68 0.85 0.78 0.85 0.77 0.62  0.80   
Chie et al 2004*  Lung                    0.83 
Galalae et al 
2004 
Prostate 0.83 0.81 0.61 0.84 0.82 0.87  -  0.89 0.85   
Fitzsimmons  
et al 2005 
Pancreatic  0.83 0.90 0.68 0.87 0.72 0.89  0.82 0.81 0.89   
Galalae et al 
2005 
Breast  0.60 0.78 0.65 0.81 0.78 0.88 0.82 0.66 0.91   
Luo et al 2005  Hetero-
genous 
0.62 0.87 0.19 0.86 0.83 0.91 0.82 0.68  0.84   




0.78 0.74 0.42 0.84 0.68 0.77 0.86 0.71  0.78   





0.82 0.74 0.87 0.80 0.80 0.96 0.89 0.97  0.79   
Brabo et al 
2006* 
Lung            0.79 
Nowak et al 
2006 
Lung 0.52  >0.70  0.51  >0.70  >0.70  >0.70  >0.70  >0.70  >0.70   




0.87 0.82 0.65 0.84 0.79 0.89  0.87  -  -   
Nicklasson et al 
2007 
Lung  0.79 0.87 0.57 0.84 0.80 0.87 0.82 0.84  -  0.76 
Current study  Lung  0.87  0.94  0.68  0.90 0.86 0.94 0.91` 0.67 0.87  0.89 
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